Literature DB >> 9247762

Aldosterone, salt and cardiac fibrosis.

J W Funder1.   

Abstract

The classical effects of aldosterone are mediated via epithelial mineralocorticoid receptors (MR), protected against cortisol/corticosterone occupancy and activation by the enzyme 11 beta hydroxysteroid dehydrogenase. The pathophysiological effects of aldosterone on non-epithelial tissues, in contrast, are mediated via unprotected MR in which occupancy by cortisol/corticosterone antagonises the effect of aldosterone. Aldosterone raises blood pressure by occupying MR in the circumventricular region of the brain, an effect antagonised by concomitant intracerebroventricular (ICV) infusion of similar doses of corticosterone. Peripheral infusion of aldosterone to salt loaded rats causes hypertension, cardiac hypertrophy and cardiac fibrosis; concomitant ICV infusion of the MR antagonist RU28318 abolishes the aldosterone-induced hypertension, but does not affect cardiac hypertrophy or fibrosis. These peripheral effects of aldosterone are presumably via cardiac MR; high glucose/PKC modulated, aldosterone-specific effects on protein synthesis have recently been demonstrated as direct MR-mediated actions on cultured neonatal rat cardiomyocytes. The pathophysiologic effects of aldosterone via nonepithelial MR have a time course of days/weeks rather than hours, reflect occupancy of only a small percentage of such receptors, and require salt loading. How the effects of salt loading are transduced in such circumstances remains to be explored.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247762     DOI: 10.3109/10641969709083193

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  8 in total

Review 1.  Aldosterone antagonists in the treatment of hypertension and target organ damage.

Authors:  S Rajagopalan; B Pitt
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

2.  Cortex sparing laparoscopic adrenalectomy in a patient with Conn's syndrome.

Authors:  Fahri Yetişir; A Ebru Salman; Alper Özkardeş; Mehmet Tokaç; Burak Çiftçi; Mehmet Kılıç
Journal:  Ulus Cerrahi Derg       Date:  2013-03-01

3.  Evidence for a novel natriuretic peptide receptor that prefers brain natriuretic peptide over atrial natriuretic peptide.

Authors:  M F Goy; P M Oliver; K E Purdy; J W Knowles; J E Fox; P J Mohler; X Qian; O Smithies; N Maeda
Journal:  Biochem J       Date:  2001-09-01       Impact factor: 3.857

4.  Changing pattern of the intraoperative blood pressure during endoscopic adrenalectomy in patients with Conn's syndrome.

Authors:  I Gockel; A Heintz; R Kentner; C Werner; C Wetner; Th Junginger
Journal:  Surg Endosc       Date:  2005-09-29       Impact factor: 4.584

5.  Spironolactone attenuates experimental uremic cardiomyopathy by antagonizing marinobufagenin.

Authors:  Jiang Tian; Amjad Shidyak; Sankaridrug M Periyasamy; Steven Haller; Mohamed Taleb; Nasser El-Okdi; Jihad Elkareh; Shalini Gupta; Sabry Gohara; Olga V Fedorova; Christopher J Cooper; Zijian Xie; Deepak Malhotra; Alexei Y Bagrov; Joseph I Shapiro
Journal:  Hypertension       Date:  2009-11-02       Impact factor: 10.190

Review 6.  Salt craving: the psychobiology of pathogenic sodium intake.

Authors:  Michael J Morris; Elisa S Na; Alan Kim Johnson
Journal:  Physiol Behav       Date:  2008-04-13

Review 7.  Anesthetic considerations on adrenal gland surgery.

Authors:  Rudin Domi; Hektor Sula; Myzafer Kaci; Sokol Paparisto; Artan Bodeci; Astrit Xhemali
Journal:  J Clin Med Res       Date:  2014-10-16

8.  The effect of eplerenone on the renin-angiotensin-aldosterone system of rats with thyroid dysfunction.

Authors:  Kawa Dizaye; Zana A Mustafa
Journal:  J Pharm Pharmacol       Date:  2019-10-03       Impact factor: 3.765

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.